Tocilizumab

Generic Name: Tocilizumab

Brand Names: Actemra, RoActemra, Tyenne, Tofidence

Drug Type: Biotech

Chemical Formula: -

CAS Number: 375823-41-9

Unique Ingredient Identifier: I031V2H011

Background: Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflamm...

Indication: Tocilizumab is indicated to treat moderate to severe rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.
...

Associated Conditions: Coronavirus Disease 2019 (COVID‑19), Cytokine Release Syndrome caused by CAR-T Cell Therapy, Giant Cell Arteritis (GCA), Juvenile Chronic Polyarthritis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis (SJIA), Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), Active systemic Juvenile idiopathic arthritis, Severe, active Rheumatoid arthritis

Associated Therapies: Monotherapy

Clinical Trials

Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab

First Posted Date: 2012-10-31

Last Posted Date: 2019-05-15

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 74

Registration Number: NCT01717859

Locations: 🇺🇸
UCLA David Geffen School of Medicine, Division of Rheumatology, Los Angeles, California, United States

Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study

Phase 1

Conditions: Pan-uveitis
Posterior Uveitis
Intermediate Uveitis

Interventions: Drug: Tocilizumab

First Posted Date: 2012-10-30

Last Posted Date: 2017-04-28

Lead Sponsor: University of Nebraska

Target Recruit Count: 36

Registration Number: NCT01717170

Locations: 🇺🇸
Truhlsen Eye Institute, University Of Nebraska Medical Center, Omaha, Nebraska, United States

A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488

Phase 4

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: DMARDs
Drug: Tocilizumab

First Posted Date: 2012-10-29

Last Posted Date: 2017-06-12

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 26

Registration Number: NCT01715831

Locations: 🇧🇷
Hospital Universitario Cassiano Antonio Moraes - UFES; Reumatologia, Vitoria, ES, Brazil
🇧🇷
Centro Mineiro de Pesquisa - CMIP, Juiz de Fora, MG, Brazil
🇧🇷
Universidade Federal de Sao Paulo - UNIFESP; Reumatologia, Sao Paulo, SP, Brazil

and more 6 locations

A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: tocilizumab

First Posted Date: 2012-10-12

Last Posted Date: 2018-09-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 71

Registration Number: NCT01705730

Locations: 🇧🇪
CH EpiCURA Site Ath, Ath, Belgium
🇧🇪
CHU Brugmann (Victor Horta), Bruxelles, Belgium
🇧🇪
ASZ Aalst, Aalst, Belgium

and more 14 locations

An Open-Label Trial of Tocilizumab in Schizophrenia

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: Tocilizumab

First Posted Date: 2012-10-02

Last Posted Date: 2021-07-29

Lead Sponsor: Brian Miller

Target Recruit Count: 8

Registration Number: NCT01696929

Locations: 🇺🇸
Georgia Health Sciences University, Augusta, Georgia, United States

Tocilizumab for the Treatment of Behcet's Syndrome

Phase 2

Terminated

Conditions: Behcet Syndrome

Interventions: Drug: Tocilizumab

First Posted Date: 2012-09-26

Last Posted Date: 2019-02-15

Lead Sponsor: NYU Langone Health

Target Recruit Count: 1

Registration Number: NCT01693653

Locations: 🇺🇸
NYU Center for Musculoskeletal Care, New York, New York, United States

A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab

First Posted Date: 2012-08-21

Last Posted Date: 2016-10-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 43

Registration Number: NCT01670045

A Long Term Extension Study of WA19926 (NCT01007435) of Tocilizumab (RoActemra/Actemra) in Participants With Early, Moderate to Severe Rheumatoid Arthritis (RA)

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab

First Posted Date: 2012-08-20

Last Posted Date: 2019-05-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 23

Registration Number: NCT01668966

Locations: 🇧🇷
Centro de Estudos em Terapias Inovadoras - CETI, Curtiba, PR, Brazil
🇧🇷
CIP - Centro Internacional de Pesquisa, Goiania, GO, Brazil
🇧🇷
Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil

and more 3 locations